Đánh giá kết quả phác đồ Etoposide kết hợp nhóm Platinum điều trị ung thư phổi tế bào nhỏ giai đoạn lan tràn tại Bệnh viện Bạch Mai=Evaluation of the results of the etoposide regimen combined with platinum group for treatment of spreading stage of small cell lung cancer at Bach Mai Hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Hữu Dương Lê, Văn Long Lê, Viết Nam Lê, Cẩm Phương Phạm, Văn Thái Phạm, Thị Huyền Trang Võ

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.147-153

Bộ sưu tập: Metadata

ID: 245925

Thêm vào giỏ

Đánh giá kết quả của phác đồ Etoposide kết hợp nhóm Platinum trong điều trị ung thư phổi tế bào nhỏ giai đoạn lan tràn, nhận xét một số tác dụng không mong muốn của phác đồ. Đối tượng: Gồm 36 bệnh nhân ung thư phổi tế bào nhỏ giai đoạn lan tràn từ tháng 01/2021 đến tháng 1/2023. Phương pháp: Nghiên cứu mô tả hồi cứu. Kết quả: Tuổi trung bình là 64,3 tuổi, hầu hết là nam giới. Về cải thiện triệu chứng cơ năng: đa số bệnh nhân đều có sự ổn định bệnh sau điều trị (58,3%). Theo tiêu chuẩn RECIST, tỷ lệ bệnh nhân đáp ứng 1 phần chiếm đa số (52,8%), đáp ứng hoàn toàn (19,4%), bệnh tiến triển (19,4%), bệnh ổn định (8,3%). Tác dụng không mong muốn trên hệ huyết học chỉ gặp mức độ nhẹ (độ I-II), ngoài hệ tạo huyết hay gặp nhất là nôn, buồn nôn và viêm phổi với tỉ lệ lần lượt là 33,3 % và 13,9 %. Kết luận: Ung thư phổi tế bào nhỏ giai đoạn lan tràn thường gặp nam giới, phác đồ Etoposid kết hợp nhóm platinum cho thấy hiệu quả tốt, độc tính thường ở mức độ nhẹ.To evaluate the results of the Etoposide regimen combined with the Platinum group in the treatment of extensive stage small cell lung cancer, and to comment on some undesirable effects of the regimen. Subjects: Including 36 patients with extensive stage small cell lung cancer from January 2021 to January 2023. Methods: Retrospective descriptive study. Results: The average age was 64.3 years old, mostly male. Regarding the improvement of functional symptoms: the majority of patients had stable disease after treatment (58.3%). According to RECIST criteria, the proportion of patients with partial response was the majority (52.8%), complete response (19.4%), progressive disease (19.4%), and stable disease (8.3%). Hematological adverse effects were only mild (grade I-II), the most common side effects were vomiting, nausea and pneumonia with rates of 33.3% and 13.9%, respectively. Conclusions: Extensive stage small cell lung cancer is common in men, the Etoposide regimen combined with platinum group showed good effectiveness, toxicity was usually mild.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR